BofA analyst Alec Stranahan downgraded Y-mAbs Therapeutics (YMAB) to Underperform from Neutral with a price target of $3, down from $12.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
- Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
- Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
- Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
- Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue